ProQR Historical Cash Flow
| PRQR Stock | USD 1.40 0.03 2.10% |
Analysis of ProQR Therapeutics cash flow over time is an excellent tool to project ProQR Therapeutics future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Change In Cash of 32 M or Stock Based Compensation of 4 M as it is a great indicator of ProQR Therapeutics ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining ProQR Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether ProQR Therapeutics is a good buy for the upcoming year.
ProQR |
About ProQR Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in ProQR balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which ProQR's non-liquid assets can be easily converted into cash.
ProQR Therapeutics Cash Flow Chart
Add Fundamental
Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Most accounts from ProQR Therapeutics' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into ProQR Therapeutics current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ProQR Therapeutics BV. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in producer price index. At this time, ProQR Therapeutics' Change In Cash is relatively stable compared to the past year. As of 03/30/2025, Stock Based Compensation is likely to grow to about 4 M, while Capital Expenditures is likely to drop slightly above 943.5 K.
ProQR Therapeutics cash flow statement Correlations
Click cells to compare fundamentals
ProQR Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
ProQR Therapeutics cash flow statement Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Capital Expenditures | 924K | 484K | 708K | 1.4M | 1.4M | 943.5K | |
| Total Cash From Financing Activities | 14.5M | 136.8M | (30.9M) | (2.3M) | 70.3M | 40.9M | |
| End Period Cash Flow | 75.8M | 187.5M | 94.8M | 118.9M | 149.4M | 98.4M | |
| Change In Cash | (36.1M) | 111.7M | (92.7M) | 24.2M | 30.5M | 32.0M | |
| Net Borrowings | 1.5M | 13.8M | 26.8M | (45.0M) | (40.5M) | (38.5M) | |
| Stock Based Compensation | 7.8M | 6.2M | 2.9M | 3.1M | 2.5M | 4.0M | |
| Free Cash Flow | (48.0M) | (26.5M) | (69.2M) | 20.2M | (37.8M) | (39.7M) | |
| Change In Working Capital | (5.0M) | 25.0M | (5.4M) | 49.0M | (13.3M) | (12.6M) | |
| Begin Period Cash Flow | 112.0M | 75.8M | 187.5M | 94.8M | 118.9M | 92.9M | |
| Total Cashflows From Investing Activities | (580K) | (924K) | (425K) | (702K) | (807.3K) | (847.7K) | |
| Other Cashflows From Financing Activities | 735K | 1.5M | 34K | 354K | 223K | 211.9K | |
| Depreciation | 2.4M | 2.3M | 2.5M | 2.5M | 2.8M | 1.7M | |
| Other Non Cash Items | (5.8M) | 2.0M | (3.7M) | (5.4M) | (474K) | (497.7K) | |
| Total Cash From Operating Activities | (47.1M) | (26.0M) | (68.5M) | 21.5M | (36.4M) | (38.2M) | |
| Change To Operating Activities | 1.7M | (5.1M) | 25.0M | (5.4M) | (6.2M) | (5.9M) | |
| Net Income | (46.6M) | (61.7M) | (64.9M) | (27.5M) | (27.8M) | (29.2M) | |
| Change To Netincome | 8.8M | 2.3M | 8.3M | (484K) | (556.6K) | (528.8K) | |
| Investments | (924K) | (425K) | (702K) | 4.3M | (4.1M) | (3.9M) |
Pair Trading with ProQR Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ProQR Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ProQR Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with ProQR Stock
Moving against ProQR Stock
| 0.56 | LUCD | Lucid Diagnostics | PairCorr |
| 0.56 | WM | Waste Management | PairCorr |
| 0.55 | GE | GE Aerospace | PairCorr |
| 0.44 | PLX | Protalix Biotherapeutics | PairCorr |
The ability to find closely correlated positions to ProQR Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ProQR Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ProQR Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ProQR Therapeutics BV to buy it.
The correlation of ProQR Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ProQR Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ProQR Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ProQR Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for ProQR Stock Analysis
When running ProQR Therapeutics' price analysis, check to measure ProQR Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ProQR Therapeutics is operating at the current time. Most of ProQR Therapeutics' value examination focuses on studying past and present price action to predict the probability of ProQR Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ProQR Therapeutics' price. Additionally, you may evaluate how the addition of ProQR Therapeutics to your portfolios can decrease your overall portfolio volatility.